Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly ...
WEB2 days ago · 2seventy bio, Inc (NASDAQ:TSVT) and its partner Bristol Myers Squibb & Co (NYSE:BMY), will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study of Abecma (idecabtagene vicleucel; ide-cel ...
Struggling 2Seventy scraps a key cancer study - BioPharma Dive
WEB2 days ago · 2Seventy bio, the cancer-focused drugmaker spun out of Bluebird bio, has decided to stop enrolling a key study that’s been evaluating its multiple myeloma therapy Abecma earlier in the treatment process. The decision announced Wednesday was made, in part, to help ensure 2Seventy breaks even financially next year.
2seventy, Bristol Myers Drop Abecma Study in Newly
WEB2 days ago · 2seventy bio and Bristol Myers Squibb are pulling the plug on a late-stage study of their Abecma gene therapy in certain people newly diagnosed with the blood cancer multiple myeloma. 2seventy on ...
BMS, 2seventy scrap Abecma trial in first-line multiple myeloma
WEB2 days ago · Bristol and its partner 2seventy bio have decided to pull the plug on the phase 3 KarMMa-9 trial. The trial had been evaluating Abecma as a first-line maintenance treatment in patients with newly ...
2seventy bio Provides Update on KarMMa-9 Study and Previews
WEB2 days ago · 2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance September 25, 2024 | 19 min read
2seventy bio Provides Update on KarMMa-9 Study and Previews …
WEB2 days ago · Twitter Facebook LinkedIn Sep 25 2024 11:00 BST 2seventy and Bristol Myers Squibb discontinue enrollment in Phase 3 KarMMa-9 study Decision results in over $80 million in anticipated cost savings for 2seventy over the next several years and accelerates path to breakeven in 2025 Expanded 3L+ label drives re-acceleration in Abecma U.S. revenues with third quarter revenue expected to grow ...
2seventy bio Announces Completion of Oncology and …
WEBApr 1, 2024 · Going forward, 2seventy bio will focus exclusively on the commercialization and development of Abecma(idecabtagene vicleucel), its BCMA-targeted CAR T cell therapy for multiple myeloma, in ...
2seventy bio Announces Strategic Restructuring to Prioritize …
WEBSep 12, 2023 · 2seventy bio Announces Strategic Restructuring to Prioritize Growth of Abecma, Streamline Pipeline Advancement and Preserve Financial Runway. Approximately 40% workforce reduction combined with related actions expected to achieve $130+ million savings in the 2024-2025 period; projected cash runway into …
2seventy bio Announces New Strategic Path Forward
WEBJan 30, 2024 · CAMBRIDGE, Mass. -- (BUSINESS WIRE)--Jan. 30, 2024-- 2seventy bio, Inc. (Nasdaq: TSVT), announced today that it is transforming the Company to focus exclusively on the commercialization and development of Abecma (idecabtagene vicleucel), its BCMA-targeted CAR T therapy for multiple myeloma.
2seventy, Bristol Myers Discontinue Enrollment In Phase 3
WEB2 days ago · (RTTNews) - 2seventy bio (TSVT) announced that the company, in partnership with study sponsor Bristol Myers Squibb, will discontinue enrollment in Phase 3 KarMMa-9 study evaluating Abecma with ...